XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Transactions
 9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
Plumbline Life Sciences, Inc.
The Company owned 597,808 shares of common stock in PLS as of September 30, 2023, representing an ownership interest of 17.8%, and one of the Company's directors, Dr. David B. Weiner, acts as a consultant to PLS.
Revenue recognized from PLS consists of milestone, license and patent fees. For both the three and nine months ended September 30, 2023, the Company recognized no revenue from PLS and for the three and nine months ended September 30,
2022 recognized revenue of $7,000 and $22,000, respectively. At each of September 30, 2023 and December 31, 2022, the Company had an accounts receivable balance of $59,000 due from PLS.
The Wistar Institute
The Company's director Dr. David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.
In March 2016, the Company entered into collaborative research agreements with Wistar for preventive and therapeutic DNA-based immunotherapy applications and products developed by Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreements. In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar with the same terms. The Company has the exclusive right to in-license new intellectual property developed under this agreement.
In 2020, the Company received a $10.7 million sub-grant through Wistar, which was amended in 2021 to $13.6 million, for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding extended through August 2024. The sub-grant also includes an option for an additional $1.6 million in funding through September 2025.
In December 2022, the Company received a $1.2 million sub-grant through Wistar with funding through November 2023, with an option for an additional $5.4 million in funding through November 2027. The Company will support the Wistar lead consortium in the research and development of synthetic DNA-launched immunogens for HIV.
Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three and nine months ended September 30, 2023, the Company recorded $316,000 and $705,000, respectively, and for the three and nine months ended September 30, 2022 the Company recorded $824,000 and $6.3 million, respectively, as contra-research and development expense from Wistar.
Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 13). Research and development expenses recorded from Wistar for the three and nine months ended September 30, 2023 were $407,000 and $1.3 million, respectively. Research and development expenses recorded from Wistar for the three and nine months ended September 30, 2022 were $474,000 and $1.4 million, respectively. At September 30, 2023 and December 31, 2022, the Company had an accounts receivable balance of $2.1 million and $9.9 million, respectively, and an accounts payable and accrued liability balance of $712,000 and $1.2 million, respectively, related to Wistar. As of September 30, 2023, the Company recorded $22,000 as deferred grant funding and $35,000 as prepaid expenses on the condensed consolidated balance sheet related to Wistar.